GlobalData on MSN6d
Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MM
Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...
Daily5d
Sanofi Sarclisa combo gets Japanese nod for newly diagnosed multiple myeloma
Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...
Pharmabiz6d
Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma
Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...
pharmaphorum3d
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...
pharmaphorum1d
ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche
Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myeloma, but new data from the ...
DelveInsight Business Research, LLP: Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The rising prevalence of genetic disorders and cancer, along ...
Pharmaceutical Technology6d
Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MM
Sanofi’s Sarclisa has received approval in more than 50 nations and regions. Credit: LCV/Shutterstock. Sanofi’s Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and ...